The Bristol drug's availability for adjuvant bladder cancer threw Keynote-123 out of kilter.

CG Oncology and Arrivent pull off US flotations, and both offer speculative investment cases.

Another KRAS G12D inhibitor hits the clinic, while Zai Lab hopes to banish the spectre of Rova-T. 

A study to back accelerated approval is to start next year, but the prospect of seeing a fully greenlit Padcev before then looms large.